{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:57:01Z","timestamp":1648702621680},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/naika.102.594","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T01:46:22Z","timestamp":1394415982000},"page":"594-599","source":"Crossref","is-referenced-by-count":0,"title":["1. Current Therapies for Liver Cirrhosis and Hepatocellular Carcinoma"],"prefix":"10.2169","volume":"102","author":[{"given":"Isao","family":"Sakaida","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Tajika M, et al: Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 18 (3): 229-234, 2002.","DOI":"10.1016\/S0899-9007(01)00754-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Muto Y, et al: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3 (7): 705-713, 2005.","DOI":"10.1016\/S1542-3565(05)00017-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Davila JA, et al: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54 (4): 533-539, 2005.","DOI":"10.1136\/gut.2004.052167"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Okita K, et al: A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol 45 (9): 979-987, 2010.","DOI":"10.1007\/s00535-010-0240-6"},{"key":"6"},{"key":"7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Shiina S, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107 (4): 569-577, 2012.","DOI":"10.1038\/ajg.2011.425"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Llovet JM, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4): 378-390, 2008.","DOI":"10.1056\/NEJMoa0708857"},{"key":"10"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yamasaki T, et al: Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 365 (6): 576-578, 2011.","DOI":"10.1056\/NEJMc1105726"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Terai S, et al: Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24 (10): 2292-2298, 2006.","DOI":"10.1634\/stemcells.2005-0542"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/3\/102_594\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T16:59:25Z","timestamp":1621443565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/3\/102_594\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.102.594","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}